CLINICAL TRIALS PROFILE FOR DALIRESP
✉ Email this page to a colleague
All Clinical Trials for DALIRESP
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01433666 ↗ | Roflumilast and Cognition | Completed | ZonMw: The Netherlands Organisation for Health Research and Development | Phase 2 | 2011-09-01 | The aim of the current project is to validate PDE4 inhibitors as a target for cognition enhancers (proof-of-concept) using a translational behaviour-EEG approach. The project will demonstrate whether memory, but also attention, information processing or executive function improves with the PDE4 inhibitor roflumilast in healthy humans. |
| NCT01433666 ↗ | Roflumilast and Cognition | Completed | Maastricht University Medical Center | Phase 2 | 2011-09-01 | The aim of the current project is to validate PDE4 inhibitors as a target for cognition enhancers (proof-of-concept) using a translational behaviour-EEG approach. The project will demonstrate whether memory, but also attention, information processing or executive function improves with the PDE4 inhibitor roflumilast in healthy humans. |
| NCT01443845 ↗ | Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) | Completed | AstraZeneca | Phase 4 | 2011-09-30 | To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD. |
| NCT01443845 ↗ | Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) | Completed | Forest Laboratories | Phase 4 | 2011-09-30 | To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD. |
| NCT01572948 ↗ | A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD) | Completed | University of Alabama at Birmingham | N/A | 2012-06-01 | The purpose of the study is to propose that roflumilast is associated with meaningful reductions in biomarkers of pulmonary inflammation and sputum neutrophilia, including confirmation of previously described results, and correlate these findings with improvement in pulmonary function, sputum scores, and quality of life in stable moderate to severe COPD. The investigators aim to demonstrate this regardless of concomitant medication use, including inhaled corticosteroids. Additionally, the investigators hope to provide a mechanistic pathway by which these effects occur. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DALIRESP
Condition Name
Clinical Trial Locations for DALIRESP
Trials by Country
Clinical Trial Progress for DALIRESP
Clinical Trial Phase
Clinical Trial Sponsors for DALIRESP
Sponsor Name
